Abstract: |
It was previously shown that the NF-κB pathway is downstream of oncogenic Notch1 in T cell acute lymphoblastic leukemia (T-ALL). Here, we visualize Notch-induced NF-κB activation using both human T-ALL cell lines and animal models. We demonstrate that Hes1, a canonical Notch target and transcriptional repressor, is responsible for sustaining IKK activation in T-ALL. Hes1 exerts its effects by repressing the deubiquitinase CYLD, a negative IKK complex regulator. CYLD expression was found to be significantly suppressed in primary T-ALL. Finally, we demonstrate that IKK inhibition is a promising option for the targeted therapy of T-ALL as specific suppression of IKK expression and function affected both the survival of human T-ALL cells and the maintenance of the disease in vivo. © 2010 Elsevier Inc. |
Keywords: |
signal transduction; protein expression; unclassified drug; nonhuman; protein function; mouse; animals; mice; mice, knockout; cell survival; apoptosis; protein degradation; animal experiment; basic helix-loop-helix transcription factors; notch receptor; immunoglobulin enhancer binding protein; transcription factor hes 1; cell differentiation; homeodomain proteins; transcription factor rela; in vitro study; mice, inbred balb c; mice, inbred c57bl; animalia; nf-kappa b; receptors, notch; cell growth processes; tumor suppressor proteins; t cell leukemia; genes, tumor suppressor; i kappa b; protein cyld; synaptotagmin i; leukemia, t-cell
|